AstraZeneca’s New Bladder Cancer Treatment Aims to Reduce Death Risk by 42%
AstraZeneca has received FDA approval for a new perioperative regimen using Imfinzi (durvalumab) combined with enfortumab vedotin (EV) for adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. The approval is based on the phase 3 VOLGA trial, which showed the combination reduced the risk of death by 42% compared to surgery alone.
How the New Treatment Works for Patients
For patients with muscle-invasive bladder cancer, radical cystectomy, or bladder removal surgery, has long been the standard of care. However, about half of these patients experience a recurrence of the cancer. The new regimen offers a different approach. Patients receive three 21-day cycles of durvalumab and EV before undergoing surgery. After the cystectomy, they receive nine cycles of adjuvant durvalumab every four weeks.
Early findings from the VOLGA trial suggest this approach is effective. The combination therapy led to a pathologic complete response in 45.1% of patients, compared to 9.6% with surgery alone. This means the cancer was not found in the tissue removed during surgery in nearly half the patients who received the new combination. The encouraging part is the significant reduction in the risk of death, which is a critical goal for any cancer treatment.
Strategic Positioning in the Bladder Cancer Market
This new approval represents a strategic move for AstraZeneca in the bladder cancer market. The company is positioning its Imfinzi-EV combination as a direct competitor to other regimens, particularly those involving Merck’s Keytruda (pembrolizumab). In recent years, Keytruda has been a dominant force in oncology, and AstraZeneca’s new treatment offers an alternative for patients who cannot tolerate cisplatin chemotherapy.
The VOLGA trial specifically targeted patients who were cisplatin-ineligible or declined the chemotherapy. This is a significant patient population, as up to half of MIBC patients are ineligible for cisplatin due to impaired kidney function or other comorbidities. By focusing on this group, AstraZeneca is carving out a niche for its therapy, potentially capturing a substantial share of the market.
The Importance of Oncology to AstraZeneca’s Business
Oncology is not just a medical priority for AstraZeneca; it is a central pillar of its business strategy. The company’s oncology division generated $21.9 billion in revenue during the first nine months of 2026, accounting for 47% of its total sales. This heavy concentration on oncology underscores the importance of new treatments like the Imfinzi-EV combination for the company’s long-term financial health.
Analysts project AstraZeneca’s free cash flow to grow from around $7.1 billion in the latest twelve-month view to roughly $19.4 billion by 2030. This growth is largely expected to be driven by its oncology pipeline and successful commercialization of new drugs. The approval of the Imfinzi-EV regimen is a key milestone in this strategy, as it adds a powerful new option to its portfolio and strengthens its competitive position in the lucrative bladder cancer market.
For patients with muscle-invasive bladder cancer, this new treatment offers a promising option that could significantly improve survival outcomes. However, patients should always discuss the best course of treatment with their doctor, as individual circumstances can vary. The encouraging results from the VOLGA trial provide hope, but a consultation with a healthcare professional is essential to determine the most appropriate care plan. This new development marks an important step forward, but the encouraging part is the potential to help patients live longer, healthier lives. Patients should talk to their doctor to see if this treatment is right for them.
Sources
- AstraZeneca
- SAP Expands Collaboration with AstraZeneca to Adopt RISE with SAP and Business AI
- __symbol__ Stock Quote Price and Forecast | CNN
- Is AstraZeneca (LSE:AZN) Reasonable After Its Oncology Led Cash Flow Push?
- FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC | AJMC
Photo: D Wells (CC BY-SA 4.0)
